(VET) Vermilion Energy - Overview
Stock: Crude Oil, Natural Gas, Condensate
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.68% |
| Yield on Cost 5y | 7.89% |
| Yield CAGR 5y | 8.41% |
| Payout Consistency | 81.4% |
| Payout Ratio | 62.1% |
| Risk 5d forecast | |
|---|---|
| Volatility | 47.0% |
| Relative Tail Risk | -2.03% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.51 |
| Alpha | -5.68 |
| Character TTM | |
|---|---|
| Beta | 1.552 |
| Beta Downside | 2.255 |
| Drawdowns 3y | |
|---|---|
| Max DD | 63.38% |
| CAGR/Max DD | -0.14 |
Description: VET Vermilion Energy January 19, 2026
Vermilion Energy Inc. (NYSE: VET) is a Canadian-based upstream oil and gas producer that acquires, explores, develops, and optimizes assets across North America, Europe, and Australia. Its portfolio spans the West Pembina basin in Alberta, the Williston basin in Wyoming, the Bordeaux and Paris Basin in France, the Netherlands, Germany, Ireland, Croatia, Slovakia, Hungary, and the Cooper Basin in Australia. Founded in 1994 and headquartered in Calgary, the company operates primarily as a conventional, on-shore producer.
Key operational metrics (2023): ≈ 100 kboe/d of total production, with natural gas accounting for roughly 55 % of the mix; cash flow from operations of about $750 million; net debt of $1.2 billion (net-debt-to-cash-flow ≈ 1.6×). The firm maintains a disciplined capital budget of $300 million-$350 million for 2024, emphasizing low-cost, high-margin assets and a 70 % hedge ratio on its oil exposure to mitigate price volatility. Sector-wide drivers include global oil price cycles, tightening natural-gas demand in Europe, and increasing ESG scrutiny that pressures upstream firms to improve carbon intensity.
For a deeper quantitative assessment, the ValueRay platform offers a granular, data-driven view of VET’s valuation metrics.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: -234.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -4.78 > 1.0 |
| NWC/Revenue: -4.75% < 20% (prev 6.50%; Δ -11.25% < -1%) |
| CFO/TA 0.17 > 3% & CFO 1.02b > Net Income -234.3m |
| Net Debt (1.28b) to EBITDA (937.9m): 1.36 < 3 |
| Current Ratio: 0.81 > 1.5 & < 3 |
| Outstanding Shares: last quarter (154.9m) vs 12m ago -3.82% < -2% |
| Gross Margin: 57.22% > 18% (prev 0.48%; Δ 5673 % > 0.5%) |
| Asset Turnover: 33.15% > 50% (prev 32.77%; Δ 0.38% > 0%) |
| Interest Coverage Ratio: 1.71 > 6 (EBITDA TTM 937.9m / Interest Expense TTM 129.0m) |
Altman Z'' 0.17
| A: -0.02 (Total Current Assets 394.6m - Total Current Liabilities 489.4m) / Total Assets 5.95b |
| B: -0.26 (Retained Earnings -1.53b / Total Assets 5.95b) |
| C: 0.04 (EBIT TTM 220.9m / Avg Total Assets 6.02b) |
| D: 0.82 (Book Value of Equity 2.67b / Total Liabilities 3.25b) |
| Altman-Z'' Score: 0.17 = B |
Beneish M -3.84
| DSRI: 0.69 (Receivables 188.1m/274.3m, Revenue 2.00b/1.99b) |
| GMI: 0.85 (GM 57.22% / 48.46%) |
| AQI: 0.66 (AQ_t 0.03 / AQ_t-1 0.04) |
| SGI: 1.00 (Revenue 2.00b / 1.99b) |
| TATA: -0.21 (NI -234.3m - CFO 1.02b) / TA 5.95b) |
| Beneish M-Score: -3.84 (Cap -4..+1) = AAA |
What is the price of VET shares?
Over the past week, the price has changed by +8.39%, over one month by +25.58%, over three months by +18.90% and over the past year by +12.65%.
Is VET a buy, sell or hold?
- StrongBuy: 3
- Buy: 2
- Hold: 6
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the VET price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.6 | -5.9% |
| Analysts Target Price | 9.6 | -5.9% |
| ValueRay Target Price | 10.6 | 3.7% |
VET Fundamental Data Overview February 03, 2026
P/E Trailing = 20.1667
P/E Forward = 103.0928
P/S = 0.7396
P/B = 0.7601
P/EG = 3.58
Revenue TTM = 2.00b CAD
EBIT TTM = 220.9m CAD
EBITDA TTM = 937.9m CAD
Long Term Debt = 1.26b CAD (from longTermDebt, last quarter)
Short Term Debt = 10.1m CAD (from shortTermDebt, last quarter)
Debt = 1.33b CAD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.28b CAD (from netDebt column, last quarter)
Enterprise Value = 3.31b CAD (2.03b + Debt 1.33b - CCE 46.1m)
Interest Coverage Ratio = 1.71 (Ebit TTM 220.9m / Interest Expense TTM 129.0m)
EV/FCF = 8.89x (Enterprise Value 3.31b / FCF TTM 372.7m)
FCF Yield = 11.25% (FCF TTM 372.7m / Enterprise Value 3.31b)
FCF Margin = 18.68% (FCF TTM 372.7m / Revenue TTM 2.00b)
Net Margin = -11.74% (Net Income TTM -234.3m / Revenue TTM 2.00b)
Gross Margin = 57.22% ((Revenue TTM 2.00b - Cost of Revenue TTM 853.7m) / Revenue TTM)
Gross Margin QoQ = 58.94% (prev 52.68%)
Tobins Q-Ratio = 0.56 (Enterprise Value 3.31b / Total Assets 5.95b)
Interest Expense / Debt = 2.60% (Interest Expense 34.4m / Debt 1.33b)
Taxrate = 21.0% (US default 21%)
NOPAT = 174.5m (EBIT 220.9m * (1 - 21.00%))
Current Ratio = 0.81 (Total Current Assets 394.6m / Total Current Liabilities 489.4m)
Debt / Equity = 0.49 (Debt 1.33b / totalStockholderEquity, last quarter 2.71b)
Debt / EBITDA = 1.36 (Net Debt 1.28b / EBITDA 937.9m)
Debt / FCF = 3.43 (Net Debt 1.28b / FCF TTM 372.7m)
Total Stockholder Equity = 2.77b (last 4 quarters mean from totalStockholderEquity)
RoA = -3.89% (Net Income -234.3m / Total Assets 5.95b)
RoE = -8.45% (Net Income TTM -234.3m / Total Stockholder Equity 2.77b)
RoCE = 5.47% (EBIT 220.9m / Capital Employed (Equity 2.77b + L.T.Debt 1.26b))
RoIC = 4.07% (NOPAT 174.5m / Invested Capital 4.29b)
WACC = 7.85% (E(2.03b)/V(3.36b) * Re(11.63%) + D(1.33b)/V(3.36b) * Rd(2.60%) * (1-Tc(0.21)))
Discount Rate = 11.63% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.68%
[DCF Debug] Terminal Value 70.91% ; FCFF base≈492.3m ; Y1≈323.2m ; Y5≈147.5m
Fair Price DCF = 10.97 (EV 2.96b - Net Debt 1.28b = Equity 1.68b / Shares 153.4m; r=7.85% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -52.18 | EPS CAGR: -7.52% | SUE: -0.16 | # QB: 0
Revenue Correlation: -72.29 | Revenue CAGR: -15.78% | SUE: -0.38 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.33 | Chg30d=-0.060 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.63 | Chg30d=-0.470 | Revisions Net=-1 | Growth EPS=+52.6% | Growth Revenue=-3.1%